US Patent

US11833159 — Non-hormonal steroid modulators of NF-kB for treatment of disease

Formulation · Assigned to Reveragen Biopharma Inc · Expires 2029-05-28 · 3y remaining

Vulnerability score 56/100 Moderate — design-around opportunities exist

What this patent protects

This patent protects compounds and methods for treating neuromuscular diseases, including muscular dystrophy, and inhibiting NF-κB.

USPTO Abstract

The present invention relates to compounds and methods which may be useful as treatments of neuromuscular diseases such as muscular dystrophy, and as inhibitors of NF-κB for the treatment or prevention of muscular wasting disease, including muscular dystrophy.

Drugs covered by this patent

Patent Metadata

Patent number
US11833159
Jurisdiction
US
Classification
Formulation
Expires
2029-05-28
Drug substance claim
No
Drug product claim
Yes
Assignee
Reveragen Biopharma Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.